Abstract
Patient preparation for FDG PET studies is perhaps more critical and more complex than for any other commonly performed imaging procedure. We report a patient with normal blood glucose level prior to the execution of a PET study in which FDG uptake was virtually zero in internal organs and was very extense in large muscle groups. The patient recognizes ingestion several minutes before the test. Ten days later, a repeated PET scan with normal blood glucose level, showed a normal organs distribution of FDG.
Copyright © 2011 Elsevier España, S.L. and SEMNIM. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Artifacts
-
Blood Glucose / analysis*
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Eating / physiology
-
False Positive Reactions
-
Female
-
Fluorine Radioisotopes / pharmacokinetics*
-
Fluorodeoxyglucose F18 / pharmacokinetics*
-
Glucose Transporter Type 4 / metabolism
-
Humans
-
Insulin / metabolism
-
Insulin Secretion
-
Lymphoma, Large B-Cell, Diffuse / blood
-
Lymphoma, Large B-Cell, Diffuse / diagnostic imaging
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Middle Aged
-
Multimodal Imaging*
-
Muscle, Skeletal / diagnostic imaging*
-
Muscle, Skeletal / metabolism
-
Organ Specificity
-
Positron-Emission Tomography*
-
Prednisone / administration & dosage
-
Radiopharmaceuticals / pharmacokinetics*
-
Rituximab
-
Tissue Distribution
-
Tomography, X-Ray Computed*
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Blood Glucose
-
Fluorine Radioisotopes
-
Glucose Transporter Type 4
-
Insulin
-
Radiopharmaceuticals
-
SLC2A4 protein, human
-
Fluorodeoxyglucose F18
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone